文献速递性腺与生殖内分泌肥胖与代谢综合征糖尿病

Klinefelter综合征中代谢功能障碍相关脂肪性肝病高患病率揭示未被满足的需求

Metabolic Dysfunction-associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究为横断面研究,纳入82例Klinefelter综合征(KS)患者,评估代谢功能障碍相关脂肪性肝病(MASLD)的患病率及其与性腺功能减退、肝病和心血管风险的关系。结果显示KS患者MASLD患病率为45.1%,代谢综合征是唯一独立预测因素,且肝脏受控衰减参数(CAP)与IGF-1呈显著负相关。

要点

  • KS患者MASLD患病率达45.1%,应重视早期筛查。
  • 代谢综合征是KS患者MASLD的唯一独立预测因素。
  • CAP与IGF-1负相关,提示IGF-1可能参与肝脏脂肪变过程。

核心结论

  • KS患者中MASLD患病率高达45.1%,代谢综合征是唯一独立预测因素。
  • CAP与IGF-1呈显著负相关,与甘油三酯、胰岛素抵抗指数、腰围和BMI呈正相关。
  • MASLD组与非MASLD组心血管风险无显著差异。

研究设计与样本

  • 横断面研究,纳入82例Klinefelter综合征患者。
  • 收集人体测量学、激素及肝功能参数和腹部超声结果。
  • 46例患者亚组通过FibroScan的CAP评估肝脂肪变。
  • 心血管风险采用Score2和Score2-Diabetes评估。

主要发现

  • MASLD患病率为45.1%。
  • MASLD患者年龄更大(P < .001),BMI更高(P < .001),腰围更大(P < .001),糖尿病患病率更高(P = .004)。
  • 多因素logistic回归显示代谢综合征是MASLD唯一独立预测因素。
  • FibroScan/CAP评估中,肝脏硬度中位数为4.7 KPa,CAP中位值为244.0 ± 59.4 dB/m。
  • CAP与IGF-1负相关(P ≤ .001),与甘油三酯正相关(P = .020)、胰岛素抵抗指数正相关(P = .017)、腰围正相关(P < .001)、BMI正相关(P ≤ .001)。

关键数值与推荐

  • MASLD患病率45.1%。
  • 肝脏硬度中位数4.7 KPa。
  • CAP中位值244.0 ± 59.4 dB/m。
  • 代谢综合征为MASLD唯一独立预测因素。
  • CAP与IGF-1负相关(P ≤ .001)。

临床怎么用

  • 对KS患者应早期筛查MASLD,尤其合并代谢综合征者。
  • 关注IGF-1水平与肝脏脂肪变的关联,辅助风险分层。
  • MASLD识别有助于管理该人群代谢并发症风险。

局限性

  • 横断面设计无法推断因果关系。
  • 样本量82例,FibroScan亚组仅46例。
  • 未报告MASLD诊断的具体标准细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Klinefelter syndrome (KS) has a higher propensity for metabolic disorders and increased cardiovascular risk. The prevalence and the characteristics of metabolic dysfunction-associated steatotic liver disease (MASLD) have not been described yet in KS. OBJECTIVE: We aim to study the relationship between hypogonadism, liver diseases, and cardiovascular risk using a unique KS model. METHODS: This cross-sectional study included 82 patients with KS. Data collected included anthropometric measurements, hormonal and liver function parameters, and abdominal ultrasound findings. In a subgroup of 46 patients, hepatic steatosis was evaluated using the control attenuation parameter (CAP) via FibroScan. Cardiovascular risk was assessed using Score2 and Score2-Diabetes. RESULTS: The prevalence of MASLD in patients with KS was 45.1%. Patients with MASLD were significantly older (P < .001), had higher body mass index (P < .001), waist circumference (P < .001), and a greater prevalence of diabetes (P = .004). In multivariable logistic regression analysis, metabolic syndrome was the only independent predictor of MASLD. For FibroScan/CAP evaluation, the median liver stiffness (KPa) was 4.7. The median CAP value was 244.0 ± 59.4 dB/m. Correlation analysis revealed a significant negative relationship between CAP and IGF-1 (P ≤ .001). In contrast, CAP was positively correlated with triglycerides (P = .020), insulin resistance index (P = .017), waist circumference (P < .001), and body mass index (P ≤ .001). Cardiovascular risk showed no significant differences between the MASLD and non-MASLD groups. CONCLUSION: This first study highlights substantial MASLD prevalence in patients with KS (45.1%). Metabolic syndrome is the major independent predictor of MASLD with a negative correlation between CAP and IGF-1. Early identification of MASLD is crucial to address the elevated risk of metabolic complications in this vulnerable population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Marrone A, Allosso F, Caturano A, et al. Metabolic Dysfunction-associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need. J Clin Endocrinol Metab. 2026. PMID: 40878796. doi:10.1210/clinem/dgaf479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。